Burt's Pharmacy LLC, Newbury Park, CA

Is Burt's Pharmacy LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Burt's Pharmacy LLC hold a California pharmacy license?

The California State Board of Pharmacy lists license PHY 50828 for Burt's Pharmacy Llc, Newbury Park, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 7734 for Burt's Pharmacy LLC, Newbury Park, CA, status Active, as of Nov 15, 2026.

Has Burt's Pharmacy LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (May 23, 2023) and 1 FMD-145 letter (May 23, 2023) for Burt's Pharmacy LLC. State board actions: no California State Board of Pharmacy action on license PHY 50828 or under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026. The Colorado State Board of Pharmacy’s license dataset also lists “CLS Letter of Admonition” dated Jun 13, 2023, case 2023-1342 on nonresident license OSP 7734. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Burt's Pharmacy LLC
Location
Newbury Park, CA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
May 23, 2023
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 4 observations
State board records
License found: PHY 50828, Active

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Burt's Pharmacy LLC, a 503A facility, with 3 dated actions.

Document
May 23, 2023FMD-145 letterFMD-145 Letter Issued 05/23/2023Not linked by FDA
May 23, 2023State referral letterReferral Letter to the California State Board of Pharmacy Issued 05/23/2023FDA copy (archived)
Oct 7, 2022Form 483483 Issued 10/07/2022FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Burt's Pharmacy, LLC, Newbury Park, CA (FEI number 3011924560), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 7, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30119245601187385

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 4 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Oct 4, 2022 to Oct 7, 2022: 4 observations

Firm on the cover
Burt's Pharmacy, LLC, 2333 Borchard Rd., Newbury Park, CA 91320
FEI number
3011924560
Establishment type on the cover
producer of nonsterile drugs THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY, THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION VvITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE
FDA district office on the cover
Los Angeles District 1970 l Fairchild Irvine, CA 92612
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Non-pharmaceutical grade components are used in the formulation of non-sterile drug products.

Specifically,

A) Your firm used < Redacted B4> to produce nonsterile drugs. There is no assurance th e <Redacted B4> meets at least <Red acted B4>, USP standards for microbiological or chemical quality. Examples of drug products produced with <Red acted B4> include Meperidine HCl 10 mg/ml Oral Suspension for office u se, lot 091620 22 <Redacted B4> Dyclonine I% HCl Oral Dental Solution for office use, lo t 07 112022@ <Redacted B4 > and Sodium Chloride (23.4%) 4 mEq/mL So lu t i on, lot 09272022 <Redacted B4>

B) Your firm used <Redacted B4> as a component in Dyclonine 1 % HCl Oral Dental Solution for office use, lot 07112022@ <Redacted B4>. There was inadequate assurance this ingredient was suitable for use in an oral drug product. Inactive ingredients declared on the <Redacted B4> label include <Redacted B4> and <Redacted B4> .

Observation 2

Hazardous and non-hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.

Specifically,

A) We observed capsule equipment designated as clean with apparent loose powder and residue in the hazardous and non-hazardous production rooms. There was no documentation available to demonstrate how long the items contained the powder and residue. Examples of finished drug capsules produced and dispensed include Progesterone 90 mg capsules, lot 08052022@ <Redacted B4> Tadalafil 12.5 mg SR capsules, lot 07072022@ <Redacted B4> T3 25 mcg and T4 100 mcg capsule, Jot 09232022@ <Redacted B4> Sodium Benzoate 583 mg capsule, lot 09292022@ <Redacted B4> and Chloramphenicol 50 mg/Sulfacetamide 50 mg/Amphotericin B 5 mg capsules, lot 07082022@ <Redacted B4>

C) We observed the <Redacted B4> inside the non-hazardous production room had unknown residue on the edges of the rollers and on the inside edges of the roller housing on 10/06/22. There was no documentation of how long the residue was on the <Redacted B4> rollers. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

Specifically, your firm performs potency testing on selected products <Redacted B4>. We observed the passing potency test result for Liothyronine (T3) 25 mcg SR capsule, lot 02142022@ <Redacted B4> , BUD 08/13/22 appeared inadequate. The measured concentration was <Redacted B4>. The laboratory report indicates the final potency result of 90% was based on the <Redacted B4> <Redacted B4> was within the allowed <Redacted B4> variance from the specification for finished drug products capsules but <Redacted B4> was outside of the allowed <Redacted B4> specification for finished capsules. There was no scientific rationale to release this product after <Redacted B4> failed to meet the finished drug specification.

Observation 4

Vermin was observed in your production area.

Specifically, we observed a live spider crawling on the counter and sink inside the hazardous production room. There was an approximate 1 inch gap beneath the exterior door in the storage area. The production room door is located approximately <Redacted B4> from this exterior door with the gap at the bottom.

State board of pharmacy records

The California State Board of Pharmacy file dated Nov 6, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PHY 50828Retail PharmacyBurt's Pharmacy LlcNewbury ParkActive

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

Close but not exact board records

These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 7734OSPBurt's Pharmacy LLCNewbury Park, CAActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.